Loading the security page…
A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Pacira BioSciences, Inc. (PCRX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, revenue was 746.2m $, net income was 14.6m $. Incorporated in the United States.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Pacira BioSciences, Inc. (PCRX) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Pacira BioSciences, Inc. (PCRX) on November 13, 2026 is $36.46, 0.00% on the day. Over 52 weeks the stock traded between $18.80 and $36.67; the price now sits 99% of the way up that range. Over the past year the price changed by +54.36%. The P/E ratio is 99.19, which is above the sector median (26.12). Market capitalisation is $1.45 billion, rank 96 among 382 stocks of the same industry with a known capitalisation.
Pacira BioSciences, Inc. trades on Nasdaq under the ticker PCRX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks PCRX has traded between $18.80 and $36.67. As of 13 November 2026 the price stood 98.82% of the way from the 52-week low to the high.
Over one year PCRX shares rose 54.36%; over six months they rose 61.04%. Volatility over 90 days is 68.33%. Dividends are not included: this is price change only, as of 13 November 2026.
PCRX trades at a price-to-earnings ratio of 99.2, above the sector median of 26.1. Price to sales is 1.9, below the sector median of 3.7. Price to book is 2.2, below the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
Pacira BioSciences, Inc. reported revenue of $746M and net income of $15M over the last four quarters. Net margin is 1.96%. Revenue changed by +5.71% year over year. Earnings per share are $0.35. Market capitalisation is $1.5B.
PCRX has a return on equity of 2.18%, above the sector median of −40.58%. Return on assets is 1.18%, above the sector median of −30.08%. Operating margin is 2.66%, above the sector median of −20.96%.